Search 

CEIDR (Centre of Excellence in Infectious Diseases Research) is a partnership between the Liverpool School of Tropical Medicine (LSTM) and the University of Liverpool focused on translational partnering in infectious diseases. Liverpool has the largest concentration of translationally-focused public sector R&D expertise in infectious diseases in the UK, with a track record of working successfully with commercial partners to impact product development. Consequently, CEIDR is ideally positioned to develop partnerships between research and industry to address current and future health priorities.

CEIDR became fully operational in 2018 and will develop into the portal for external organisations to make connections, source expertise and resources in infectious diseases, building relationships with industry and academic organisations to advance drugs, vaccines and diagnostics towards market. The aim is for the CEIDR brand to become synonymous with excellence in infectious diseases R&D undertaken in LSTM, the University of Liverpool and our clinical partners in Liverpool and overseas.

Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA. CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.

CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team. BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.

With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies. CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle. 

CrystecPharma is a crystal and particle engineering company applying proprietary modified supercritical fluid (SCF) technologies to improve the performance of medicines. Our technology enables drug molecules to be crystallised in new forms and novel particles to be manufactured in ways that greatly enhance their therapeutic performance. Crystec has an enabling platform which can be applied to small and large molecules, to optimise a range of medicine dosage forms (e.g. oral, inhaled, intranasal, subcutaneous, sublingual).

Crystec works with the global pharmaceutical and health care industry to solve drug particle formation, formulation and process challenges. We are also developing our own innovative therapies in important areas of unmet clinical need, including women’s health, urology and treating respiratory disease. Crystec’s proprietary ‘mSAS’ (modified Supercritical Anti-Solvent) drug delivery technology is enabled by a highly efficient, stable and fully scalable manufacturing process and is approved by regulatory authorities. The mSAS platform creates unique opportunities to improve medicines in ways that can transform the quality of life for many patients.